FFM

Fairmount Funds Management Portfolio holdings

AUM $772M
This Quarter Return
-6.3%
1 Year Return
+35.05%
3 Year Return
+1,168.51%
5 Year Return
+1,432.11%
10 Year Return
–
AUM
$885M
AUM Growth
+$885M
Cap. Flow
+$33.9M
Cap. Flow %
3.83%
Top 10 Hldgs %
94.27%
Holding
16
New
1
Increased
2
Reduced
1
Closed
3

Top Buys

1
SYRE icon
Spyre Therapeutics
SYRE
$85.6M
2
BCYC
Bicycle Therapeutics
BCYC
$21.6M
3
COGT icon
Cogent Biosciences
COGT
$12.6M

Top Sells

1
MRUS icon
Merus
MRUS
$32.3M
2
TYRA icon
Tyra Biosciences
TYRA
$22.9M
3
GERN icon
Geron
GERN
$22M
4
TERN icon
Terns Pharmaceuticals
TERN
$8.79M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Shares
Change % 		Capital Flow
AXSM icon
1
Axsome Therapeutics
AXSM
$6.05B
$190M 21.46%
2,360,077
– –
NUVL icon
2
Nuvalent
NUVL
$5.52B
$146M 16.5%
1,924,626
– –
SYRE icon
3
Spyre Therapeutics
SYRE
$996M
$94.5M 10.67%
4,018,101
+3,639,680
+962% +$85.6M
APGE icon
4
Apogee Therapeutics
APGE
$2.17B
$80.6M 9.11%
2,048,647
– –
ELVN icon
5
Enliven Therapeutics
ELVN
$1.2B
$74.8M 8.46%
3,202,798
– –
DNTH icon
6
Dianthus Therapeutics
DNTH
$759M
$71.5M 8.08%
2,762,837
– –
KNSA icon
7
Kiniksa Pharmaceuticals
KNSA
$2.48B
$59.8M 6.76%
3,204,841
– –
COGT icon
8
Cogent Biosciences
COGT
$1.69B
$52.5M 5.93%
6,225,641
+1,500,000
+32% +$12.6M
ATXS icon
9
Astria Therapeutics
ATXS
$349M
$32.3M 3.65%
3,554,129
– –
PTGX icon
10
Protagonist Therapeutics
PTGX
$3.67B
$32.3M 3.65%
931,890
– –
VRDN icon
11
Viridian Therapeutics
VRDN
$1.5B
$24M 2.71%
1,845,813
– –
BCYC
12
Bicycle Therapeutics
BCYC
$511M
$21.6M 2.44%
+1,069,199
New +$21.6M
TERN icon
13
Terns Pharmaceuticals
TERN
$609M
$5.1M 0.58%
748,996
-1,291,004
-63% -$8.79M
GERN icon
14
Geron
GERN
$893M
– –
-6,666,667
Closed -$22M
MRUS icon
15
Merus
MRUS
$4.98B
– –
-717,254
Closed -$32.3M
TYRA icon
16
Tyra Biosciences
TYRA
$675M
– –
-1,393,329
Closed -$22.9M